Skip to main content
Sudeep Pharma Limited logo

Sudeep Pharma Limited — Investor Relations & Filings

Ticker · SUDEEPPHRM ISIN · INE0QPI01025 LEI · 335800ESH1W57DIPAN45 BSE.NS Manufacturing
Filings indexed 76 across all filing types
Latest filing 2025-11-28 Regulatory Filings
Country IN India
Listing BSE.NS SUDEEPPHRM

About Sudeep Pharma Limited

https://www.sudeeppharma.com/

Sudeep Pharma Limited specializes in the manufacturing of mineral-based excipients and active pharmaceutical ingredients (APIs). The company’s core portfolio includes high-purity mineral salts such as Calcium Phosphates, Calcium Carbonate, and Calcium Sulfate, which are utilized as essential components in solid dosage formulations and nutritional supplements. These products function as diluents, binders, and mineral sources across various applications. The organization maintains advanced production facilities compliant with international quality standards, including GMP, USP, EP, and BP. A strategic partnership with JRS Pharma enhances its technical expertise and global supply chain capabilities. Sudeep Pharma focuses on providing high-quality, regulatory-compliant mineral solutions to meet the demands of global markets, emphasizing research, development, and stringent quality control processes.

Recent filings

Filing Released Lang Actions
Intimation for Closure of Trading window w.e.f. 28th November 2025 till publication of Un-audited Financial Results for the quarter and half year ended 30th September 2025
Regulatory Filings Classification · 95% confidence The document is a formal notice addressed to stock exchanges regarding the closure of the trading window for insiders in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. It mentions the closure period related to the upcoming declaration of un-audited financial results for the quarter and half-year ending September 30, 2025. The document does not contain any financial data, results, or detailed report but is an announcement related to insider trading compliance and timing of financial results disclosure. The document length is short (1825 characters) and it serves as a regulatory announcement rather than a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS).
2025-11-28 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.